

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**康臣藥業集團有限公司**  
**CONSUN PHARMACEUTICAL GROUP LIMITED**  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 1681)**

## **VOLUNTARY ANNOUNCEMENT ACQUISITION OF 30% EQUITY INTEREST IN SHANGHAI HUAMAO PHARMACEUTICAL CO., LTD.**

This announcement is made by Consun Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide its shareholders and potential investors with the updates on the development of the business of the Group.

### **THE ACQUISITION**

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 8 June 2026, Guangzhou Consun Pharmaceutical Company Limited (“**Guangzhou Consun**”), a wholly-owned subsidiary of the Company, entered into an investment agreement (the “**Investment Agreement**”) with Shanghai Huamao Pharmaceutical Co., Ltd.\* (上海華茂藥業有限公司), a limited liability company incorporated in Shanghai, China (the “**Target Company**”), and its existing shareholders (the “**Existing Shareholders**”).

Pursuant to the agreement, Guangzhou Consun will make an aggregate investment of RMB191.4022 million through the acquisition of existing equity interests and capital increase in cash. Upon completion of the transaction, Guangzhou Consun shall hold 30% equity interest in the Target Company. The Target Company shall become an associate of the Company and the financial results of which will not be consolidated into the financial statements of the Group.

To the best of the Directors’ knowledge, information and belief, and after making all reasonable enquiries, the Target Company and the Existing Shareholders are third parties independent of and not connected with the Company and its connected persons (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

## **REASONS FOR AND BENEFITS OF ENTERING INTO THE INVESTMENT AGREEMENT**

The Target Company is a supplier of the Group. According to the information provided by the Target Company, the Target Company is a biotechnology and pharmaceutical company located in Shanghai Xinzhuang Industry Park. It is a National high-tech enterprise, a Shanghai “specialized, precise and innovative” small and medium sized enterprise, and a Shanghai Minhang district science and technology giant enterprise.

The Group’s investment in the Target Company has the following benefits:

1. Strategic premium and deep synergy of core pipelines. The strategic premium is reflected not only in financial returns, but also in the deep chemical reaction between both parties in core pipelines. Through integrating the Target Company’s technology platform in the fields of synthetic biology and precision fermentation, the Group will achieve vertical integration from active pharmaceutical ingredients to finished dosage form (FDF), while locking in the supply security of core varieties, and utilizing technological empowerment to achieve quality improvement and cost reduction of the business.
2. Market expansion and breakthroughs in the field of nephrology. The Target Company possesses strong research and development as well as industrialisation capabilities in the field of peritoneal dialysis, the quality standards of which have the potential to substitute imported originator products. Meanwhile, the Group possesses a leading domestic terminal sales network for nephrology. Both parties will leverage the advantages of the integration of starting material – FDF to improve the full-process solution from pre-dialysis intervention to post-dialysis management, continuously enhancing the competitiveness and market coverage of the nephrology.
3. Strengthening supply guarantee and growth potential of the gynaecology and pediatrics’ business. The Target Company is a leading domestic manufacturer of active pharmaceutical ingredient (API) dextran and a key raw material supplier for “Yuanli Kang”, a core product of the Group’s gynaecology and pediatrics’ pipeline. This investment can further stabilize supply and reduce dependency risks, and by leveraging the Target Company’s enzymatic lactulose technology, expand into the markets for chronic constipation and FDF of differentiated pediatrics preparation, thereby broadening the growth potential of the gynaecology and pediatrics’ business.
4. Sharing of resources in research and development and production capacity to enhance overall operational efficiency. The Target Company possesses professional research and development facilities for API, which can undertake the laboratory-scale testing, pilot-scale testing and process scale-up work for the Group’s innovative drugs, thereby avoiding redundant investment and reducing research and development costs; meanwhile, through process optimization, it can enhance the yield and quality of existing products, facilitating continuous quality improvement and cost reduction.
5. Deployment in the high-value-added synthetic biology sector. The Target Company possesses a synthetic biology platform capable of scalable production of high-value bioactive raw materials, which can serve as core raw materials for the Group’s deployment in high-unit-price consumer products such as female anti-aging and children’s health, empowering the Group to cultivate new performance growth curves.

After careful assessment, the Directors (including the independent non-executive Directors) consider that the terms of the Investment Agreement and the transactions contemplated thereunder are fair and reasonable, on normal commercial terms, and in the interests of the Company and its shareholders as a whole.

As none of the applicable percentage ratios in respect of the Equity Transfers and the Capital Increase in aggregate are more than 5%, the Equity Transfers and the Capital Increase is therefore not subject to the notification and announcement requirements under Chapter 14 of the Listing Rules.

By Order of the Board  
**Consun Pharmaceutical Group Limited**  
**AN Meng**  
*Chairman*

Hong Kong, 8 June 2026

*As at the date of this announcement, the Board comprises Mr. An Meng and Mr. Young Yuk Chuen David as executive Directors; Dr. Zhang Lihua and Professor Zhu Quan as non-executive Directors; Mr. Feng Zhongshi, Professor Li Yikai, Mr. Li Zhuoguang and Mr. Duan Weiwu as independent non-executive Directors.*